IMMP vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Immutep Limited presents a high-risk profile characterized by a Piotroski F-Score of 4/9, indicating only marginal financial stability. While the company shows strong YoY revenue growth of 91.50% and maintains a healthy current ratio of 2.97, these are overshadowed by a catastrophic operating margin of -763.71% and a total collapse in share price. The stock has lost approximately 78% of its value over the last year and 88.8% in the last month, signaling a severe lack of market confidence and a bearish technical trend of 0/100.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
IMMP vs MRK: Head-to-Head Comparison
This page compares Immutep Limited (IMMP) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.